|Carmen Valcarce, Ph.D.|
Executive Vice President, Chief Scientific Officer
Dr. Valcarce obtained her Ph.D. at the Universidad Autonoma de Madrid, Spain in 1988 under the direction of Prof. Jose M. Cuezva in the field of metabolic diseases with focus on mitochondrial development and maturation after birth. From 1989 to 1998 Dr. Valcarce completed her postdoctoral studies and held the position of Assistant Professor at the Department of Clinical Chemistry at Lund University, Sweden under the direction of Prof. Johan Stenflo. During this time, the focus of her research was to understand the structure-function relationship of the various coagulation factors as well the EGF-precursor protein. Dr. Valcarce joined Excorim AB in 1998 to pursue the development of a plasmaphoreis-like system suitable to remove anti-Gal antibodies prior to kidney xeno-transplantation. In 2000, Dr. Valcarce returned to the metabolic disease area and joined Novo Nordisk where she was the project leader of the glucokinase activator project from idea to FHD. Dr. Valcarce is the author of numerous papers and presentations, and is an inventor on several patents and patent applications.